Thanks bear for your remarkable insights!
I listened to the presentation and I was very enthused about the possibilities for zen3694 and the quality of Don's presentation.
- It seems like there are opportunities for many cancers.
- It can work with many standard of care drugs without negative consequences.
- The fact that the dosage can be increased with enzalutimide above their MTD seems like a significant feature.
- The fact that treatment can be continuous seems to be a large benefit.
- It fits within the relm of "cocktail treatments".
My selfish hope is that this very early stage, small sample research creates enough curiousity and business interest so that the standard of care pharma's will partner with Zenith and that licensening deals might evolve quickly.
This is very early stage clinical research (yet promising) so there are probably years of research to be completed. From a share liquidity POV I'd really like to see enough interest for a NASDAQ listing of one of the "Star Factories" (as SF says) e.g. zen3694.
We'll see. At least it looks promising.
Toinv
